Bristol-Myers Squibb Aktie

Bristol-Myers Squibb für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 850501 / ISIN: US1101221083

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
04.02.2021 13:14:56

Bristol Myers Squibb Raises 2021 Adj. Earnings Guidance

(RTTNews) - Bristol Myers Squibb (BMY) increased its 2021 non-GAAP EPS guidance range to $7.35 - $7.55 from $7.15 - $7.45. The company assumes worldwide revenues increasing in the high-single digits. Bristol Myers Squibb also affirmed its 2020-2025 long-term financial target.

Fourth quarter non-GAAP net earnings attributable to Bristol Myers Squibb was $3.3 billion, or $1.46 per share, compared to $2.4 billion, or $1.22 per share, prior year. year. On average, 14 analysts polled by Thomson Reuters expected the company to report profit per share of $1.41, for the quarter. Analysts' estimates typically exclude special items.

Fourth quarter revenues were $11.1 billion, an increase of 39% on a reported basis and 10% on a pro forma basis. The company said the increase was driven primarily by the impact of the Celgene Acquisition, which was completed on November 20, 2019. Analysts expected revenue of $10.73 billion, for the quarter.

Analysen zu Bristol-Myers Squibb Co.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Bristol-Myers Squibb Co. 44,62 -1,00% Bristol-Myers Squibb Co.